No change in expression was seen for Fas, however both DR4 (29% increase, P < 0.05) and DR5 (46% increase, P < 0.05) were significantly increased by selinexor on the surface of CLL cells (Fig. 4C). The gene discussed is FAS; the disease is B-cell chronic lymphocytic leukemia.